Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1%

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 64,300 shares, a drop of 37.1% from the November 15th total of 102,200 shares. Based on an average trading volume of 81,800 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.5% of the shares of the stock are short sold.

VYNE Therapeutics Stock Up 6.7 %

NASDAQ VYNE opened at $2.56 on Friday. The company has a market capitalization of $37.76 million, a price-to-earnings ratio of -2.98 and a beta of 1.37. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $3.43. The stock has a fifty day simple moving average of $2.63 and a 200 day simple moving average of $2.20.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VYNE. HC Wainwright reaffirmed a “buy” rating and issued a $5.75 target price on shares of VYNE Therapeutics in a report on Friday, November 8th. BTIG Research began coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective for the company.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.